Teva CEO foresees European migraine market catching up with the US
Due to higher discount levels than expected, the EU migraine market may soon be worth as much as the US market, according to Teva CEO Kåre Schultz.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Danish newspaper Børsen writes that the European migraine market may very well rise to the levels of the US market after the latter has seen discount increases, according to Teva Pharmaceuticals Chief Executive Kåre Schultz.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
